person · Reporting owner
Patel Tushar Bhikhubhai
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | 10% owner | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy Limited Liability Companies Controlled by Family Trusts | 61,341,678 |
Reported balance
After 2026-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 12,763,469 · Balance 61,341,678 F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 22:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 12,763,469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000898432-26-000655 · form4.xml · nonDerivative · entry 1 Patel Tushar Bhikhubhai · CIK 0001745375 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Limited Liability Companies Controlled by Family Trusts Disclosed balance after: 61,341,678 F1 · kind: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition. F1 · price: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:51 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 5,000,000 | $8.35 | $41,750,000.00 |
DisclosureSEC source: 0000898432-25-000191 · form4.xml · nonDerivative · entry 1 Patel Tushar Bhikhubhai · CIK 0001745375 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By a Limited Liability Company Controlled by a Family Trust Disclosed balance after: 48,578,209 Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass B Common Stock and Common Units · Derivative | 53,578,209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054742 · doc4.xml · derivative · entry 2 Patel Tushar Bhikhubhai · CIK 0001745375 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trusts Disclosed balance after: 0 Underlying: Class A Common Stock · 53,578,209 shares Expires not disclosed F3 · security: The Issuer of the Common Units is Amneal Pharmaceuticals, LLC. F2 · derivative.exercise_price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · derivative.exercise_date: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · derivative.expiration_date: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 23:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass A Common Stock | 53,578,209 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054742 · doc4.xml · nonDerivative · entry 1 Patel Tushar Bhikhubhai · CIK 0001745375 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trusts Disclosed balance after: 53,578,209 F1 · security: On November 7, 2023, Amneal Pharmaceuticals, Inc. (formerly known as Amneal NewCo Inc.) (the "Issuer") became the successor of Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc.) ("Old PubCo") pursuant to merger transactions, in which a subsidiary of the Issuer merged with and into Old PubCo with Old PubCo surviving and, immediately following such merger, a subsidiary of the Issuer merged with and into Amneal Pharmaceuticals, LLC ("AP"), an indirect subsidiary of the Issuer, with AP surviving. The transactions resulted in the Issuer becoming a parent holding company of Old PubCo and AP. As a result of the transactions, there is a single class of stock of the Issuer outstanding, and the proportionate economic and voting rights of security holders in the Issuer are identical to the direct and indirect economic and voting rights held in Old PubCo and AP prior to the transactions. F2 · price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.